First In Human Study Of Increasing Oral Doses Of PF-04634817
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the hypothesis that at doses and plasma concentrations which affect
pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound
is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic
profile is robust and consistent with a once or twice a day therapeutic administration.